The story of Sildenafil presents a intricate picture for investors. While the initial release generated significant gains, the end of its patent opened the avenue to cheaper versions, dramatically diminishing revenue. https://bookmarkforest.com/story21558203/the-copyright-and-pharma-a-precarious-bet